Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Non-Current Deffered Revenue (2016 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Non-Current Deffered Revenue for 9 consecutive years, with $3.5 million as the latest value for Q4 2023.

  • For Q4 2023, Non-Current Deffered Revenue changed N/A year-over-year to $3.5 million; the TTM value through Dec 2023 reached $3.5 million, changed N/A, while the annual FY2023 figure was $3.5 million, N/A changed from the prior year.
  • Non-Current Deffered Revenue hit $3.5 million in Q4 2023 for Cartesian Therapeutics, down from $4.0 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $51.5 million in Q3 2020 and bottomed at $3.5 million in Q4 2023.
  • Average Non-Current Deffered Revenue over 5 years is $16.4 million, with a median of $14.7 million recorded in 2019.
  • Year-over-year, Non-Current Deffered Revenue skyrocketed 22259.7% in 2019 and then tumbled 72.9% in 2022.
  • Cartesian Therapeutics' Non-Current Deffered Revenue stood at $14.7 million in 2019, then surged by 163.94% to $38.7 million in 2020, then tumbled by 70.53% to $11.4 million in 2021, then crashed by 52.39% to $5.4 million in 2022, then tumbled by 34.92% to $3.5 million in 2023.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $3.5 million, $4.0 million, and $4.9 million for Q4 2023, Q3 2023, and Q2 2023 respectively.